Epigenetic Reprogramming: Sinclair's ER-100 & the Age Reversal Frontier

For the past century, aging was treated as a one-way street. Cells accumulate damage, epigenetic instructions degrade, and biological function declines — irreversibly. Then David Sinclair's lab at Harvard asked a different question: what if the damage isn't the problem? What if it's just noise interfering with a signal that's still intact?

That question — heterodox, carefully tested, now increasingly validated — is driving the most exciting and controversial development in longevity science: epigenetic reprogramming. And at the center of the human translation effort sits a compound known as ER-100.

This article covers the science from first principles: what epigenetic reprogramming is, what Sinclair's research has actually demonstrated, what ER-100 is and what evidence exists for it, and what the honest assessment of the human aging reversal frontier looks like in 2026.

What Is Epigenetic Reprogramming?

To understand epigenetic reprogramming, you need to understand what epigenetics is and why it matters for aging.

Your DNA is essentially fixed from birth — roughly 3 billion base pairs encoding the same genetic sequence in every cell of your body. But your cells are not identical. A liver cell and a neuron carry the same genome but behave completely differently. What controls this? Epigenetics — the layer of molecular "marks" on and around DNA that determine which genes are expressed, when, and at what level.

These epigenetic marks — primarily DNA methylation patterns and histone modifications — act like a cellular instruction manual. They tell each cell what kind of cell it is and what it should do. And unlike DNA itself, they change over time in response to environment, behavior, and age.

The Epigenetic Aging Clock

In 2013, UCLA biostatistician Steve Horvath published a landmark paper demonstrating something remarkable: methylation patterns across specific sites in the genome change so predictably with age that they can be used as an accurate biological clock. The Horvath Clock could estimate a person's biological age from a blood or tissue sample with striking precision — often within a few years of chronological age.

Subsequent "clocks" — DunedinPACE, GrimAge, PhenoAge — refined this further, measuring not just biological age but the rate at which someone is aging, and correlating clock readings with mortality risk, disease onset, and healthspan outcomes.

These clocks established something critical: biological age and chronological age diverge. Two 50-year-olds can have biological ages of 42 and 61. The gap between them predicts health outcomes better than calendar age alone. And if biological age can be measured, the question becomes: can it be moved?

Sinclair's Information Theory of Aging

David Sinclair's contribution to framing this question is his Information Theory of Aging, introduced in his 2019 book Lifespan and developed across two decades of peer-reviewed research.

The core thesis: aging is primarily caused by the loss of epigenetic information, not the loss or mutation of the underlying DNA. The genome is like a hard drive; the epigenome is like the operating system. As we age, the OS becomes increasingly corrupted — not because the data is gone, but because the reading and execution of that data degrades.

Sinclair's lab demonstrated in 2020 (published in Cell) that this corruption can be induced artificially — by cutting DNA in mouse cells without permanently damaging the sequence itself — causing mice to age prematurely. More strikingly, the aging could be reversed. Their biological clock reading went back toward younger states after treatment.

The implication: if epigenetic information loss is the primary driver of aging, and if that information can be restored, aging itself might be reversible — not merely slowed.

Partial Reprogramming: The Yamanaka Foundation

The biological tool at the center of this reversal is partial cellular reprogramming, built on the 2006 Nobel Prize-winning discovery of Shinya Yamanaka.

Yamanaka showed that adult cells — fully differentiated, with established identity — could be reprogrammed into pluripotent stem cells (capable of becoming any cell type) by introducing just four transcription factors: Oct4, Sox2, Klf4, and c-Myc. These factors essentially erased the cell's epigenetic history and reset it to an embryonic-like state.

The problem with complete Yamanaka reprogramming for aging applications: it also erases cellular identity. A reprogrammed liver cell forgets it's a liver cell. That's the basis of induced pluripotent stem cell (iPSC) therapy — useful for regenerative medicine, but not what you want systemically in a living organism.

The Partial Reprogramming Insight

The breakthrough insight — and the intellectual foundation of Sinclair's ER-100 work — was that brief, incomplete exposure to reprogramming factors could reset epigenetic age markers without erasing cellular identity.

Applied for a short enough window, the Yamanaka factors appear to "rewind" the epigenetic clock — reversing methylation patterns toward younger states — while leaving the cell's fundamental identity intact. The cell still knows it's a liver cell or a neuron; it just operates more like a younger version of itself.

Sinclair's lab demonstrated this concept dramatically in a 2020 Nature paper: they used a modified set of Yamanaka factors (OSK — Oct4, Sox2, Klf4, omitting c-Myc to reduce cancer risk) delivered via an adeno-associated virus to aged mice with glaucoma. The treatment restored vision by reversing the epigenetic age of retinal ganglion cells. The cells didn't grow back — they rejuvenated.

"We've shown that neurons can be rejuvenated, and the clock can be reversed, even in the eye. We believe we're going to be able to reverse aging throughout the whole body." — David Sinclair, Harvard Medical School, 2020

What Is ER-100?

ER-100 — short for Epigenetic Reprogramming compound 100 — is not a single molecule but a protocol-level designation for a specific combination approach to partial cellular reprogramming designed for human application.

The precise formulation details are proprietary and actively under investigation, but the published science and clinical documentation point to a few consistent elements:

The "100" designation reportedly refers to a target threshold — a 10% reduction in biological age markers across 10 validated epigenetic measurements — though the protocol has evolved since its initial documentation.

How It Differs from Earlier Longevity Protocols

What separates ER-100 from earlier Sinclair-associated protocols (primarily NAD+/NMN supplementation and sirtuin activation) is the incorporation of active reprogramming rather than passive support of existing cellular machinery.

Prior approaches — NMN, resveratrol, fasting protocols — work by maintaining or restoring the function of aging cellular systems. ER-100-style reprogramming works by attempting to reset the epigenetic state itself. The analogy: earlier approaches patch the aging operating system; partial reprogramming reinstalls it from a younger backup.

What the Human Trial Data Shows

This is where the conversation requires precision, because the field moves fast and the marketing frequently outruns the evidence.

Verified Human Findings (2025–2026)

As of 2026, human data on epigenetic reprogramming is early but accumulating. Key verified findings:

Eye restoration trial (Phase I safety): Sinclair's OSK optic nerve restoration approach has completed initial human safety evaluation. No serious adverse events were reported in the first cohort. Efficacy data on vision restoration is expected in late 2026.

Epigenetic clock reversal in skin cells: Multiple published studies have demonstrated that partial reprogramming signals can be applied to human skin cells in vitro with measurable epigenetic age reversal. The cells don't just look younger on a clock — they demonstrate functional improvements in collagen synthesis, wound healing response, and inflammatory signaling.

Altos Labs systemic safety data: Altos Labs — the $3B biotech founded in 2022 to pursue whole-body reprogramming — has released preliminary systemic safety data from primate models. No significant tumorigenic signal was detected with tightly controlled, transient OSK exposure. This is a critical data point: uncontrolled reprogramming risks cancer. Controlled protocols, the data suggest, may be manageable.

NAD+ component human RCTs: The NAD+ precursor components of protocols like ER-100 are among the better-evidenced longevity interventions at the human level. Multiple randomized controlled trials confirm that oral NMN and NR supplementation raises NAD+ levels, with secondary effects on biomarkers including DNA repair capacity, insulin sensitivity, and inflammatory markers. See our detailed breakdown: Metformin & the TAME Trial: Longevity Science's Pivotal Moment.

What's Still Under Investigation

Honest disclosure of what the evidence doesn't yet show:

• Systemic whole-body reprogramming in humans: Not yet demonstrated at safety or efficacy level. All systemic reprogramming data in humans remains early-stage or preclinical.
• Long-term safety of repeated application: The risk window for cancer induction from partial reprogramming extends beyond what current trials have followed. Decades of follow-up will be needed.
• Clinical meaningfulness of clock reversal: Biological clock readings improving doesn't automatically mean lifespan or healthspan extends. Clock reversal is a biomarker; the endpoint is healthy function. Correlation is high, causation is still being established.
• Optimal dosing, delivery, and timing: Whether oral, IV, gene therapy, or mRNA delivery is optimal — and at what dose and frequency — remains an active research question with no settled consensus.

The Sinclair Lab's Current Focus

In 2026, the Sinclair lab's primary active research lines connect directly to the ER-100 translational program:

The ICE Mouse Model and Systemic Aging

Following the 2020 ICE (Inducible Changes to the Epigenome) mouse paper, the lab has developed an increasingly refined model of how epigenetic disruption drives systemic aging. The current focus is on identifying which epigenetic sites are most recoverable — essentially, which parts of the cellular operating system are most amenable to restoration versus permanently corrupted.

This work is critical for ER-100 because a protocol targeting non-recoverable sites would waste intervention capacity. The emerging picture: highly conserved regulatory regions — those controlling core cellular housekeeping functions — retain recovery potential even in very old cells. The more cell-type-specific regulatory regions are more variable.

The Aging Reversal in Multiple Tissue Types

The 2020 eye paper demonstrated proof of concept in retinal cells. Since then, the lab has published or presented data on reprogramming in:

• Muscle tissue: Partial reprogramming of aged muscle satellite cells improved regenerative capacity following injury in mouse models.
• Kidney tissue: Epigenetic reset in aged kidney cells reduced inflammation markers and improved filtration function metrics in mouse studies.
• Brain: Most carefully watched — and most cautiously progressed — due to the complexity of neural identity and the consequences of cell identity disruption. Early data is being handled with appropriate conservatism.

Non-Viral Delivery

Early reprogramming research used viral vectors (AAV) to deliver transcription factors — effective but clinically complex. The Sinclair lab and several collaborators are actively investigating mRNA delivery as a non-viral alternative, building on the mRNA platform technology validated by COVID-19 vaccines. mRNA-based delivery would be transient by nature (mRNA degrades within days), which is precisely the brief-exposure profile that makes partial reprogramming safer than sustained expression.

The Credibility Question in Longevity Marketing

Epigenetic reprogramming is one of the most hyped areas in health and wellness — and one where the gap between marketing claims and demonstrated evidence is large enough to cause real harm.

Several companies have begun marketing "epigenetic reprogramming" products — supplements, IV formulations, proprietary protocols — under branding that implies they replicate the Sinclair lab's research. Most of these products have no connection to the published science and no peer-reviewed evidence for epigenetic reset in humans.

The signals of legitimate versus marketing-driven ER claims:

For deeper context on the tension between legitimate longevity science and wellness marketing, see our article on The Scientists Behind the Longevity Movement.

Where Epigenetic Reprogramming Fits in a Longevity Stack

For anyone building a serious, evidence-informed longevity practice, how does reprogramming science fit relative to interventions available today?

The honest answer: most people are not candidates for experimental reprogramming protocols in 2026. The clinical translation is real but early. What is accessible and directly informed by reprogramming science:

NAD+ Optimization

The NAD+ component of ER-100-style protocols is the most accessible element. Sirtuin activation — which Sinclair's lab established as central to epigenetic maintenance — requires NAD+ as a substrate. NAD+ levels decline sharply with age. Oral NMN or NR supplementation raises NAD+ levels in human trials, with secondary effects on multiple longevity biomarkers.

This isn't "epigenetic reprogramming" — it's maintenance of the cellular machinery that reprogramming protocols depend on. But it's informed by the same science and supported by human RCT data. See: The Longevity Beginner's Guide.

Senolytic Priming

Senescent cells — which accumulate with age and secrete inflammatory signals that disrupt epigenetic integrity — are cleared as part of reprogramming preparation in ER-100 protocols. Senolytic compounds (quercetin + dasatinib, fisetin at high dose) have early human evidence for senescent cell clearance. Several longevity clinics now incorporate short-course senolytic protocols as a standalone or preparatory intervention.

Epigenetic Clock Baseline

Getting a biological age measurement is increasingly accessible. Companies including TruMe, Elysium, and Chronomics offer methylation-based clock tests from a blood or saliva sample. Knowing your biological age — and tracking it over time — is the measurement infrastructure that any serious longevity intervention program needs.

This matters for the broader picture of cognitive protection and metabolic health that reprogramming research connects to. For more on the protective lifestyle interventions with strong evidence: Wellness Protocols for Dementia Prevention & Cognitive Protection.

Biomarker Panel

The blood work foundation that lets you know whether any intervention is moving the right levers. See: The Blood Work Guide for Longevity.

The Altos Labs Race and What It Means

Sinclair's lab is not the only serious player in the reprogramming space. Altos Labs, founded in 2022 with backing from Jeff Bezos, Yuri Milner, and others, assembled a scientific roster that reads like a longevity Hall of Fame: Yamanaka himself as senior scientific advisor, Juan Carlos Izpisúa Belmonte (whose lab produced some of the most advanced partial reprogramming work in mice), Vittorio Sebastiano, Concepcion Rodriguez Esteban, and others.

Altos operates under a different model than academic labs: long time horizons, institutional resources, and explicit commercial intent. Their stated goal is not to extend healthspan marginally — it is to develop cell rejuvenation medicines that can reverse biological aging in human tissue.

Turn Biotechnologies, based in Cambridge, is pursuing a more targeted approach: mRNA-based transient reprogramming of specific cell types, starting with skin and moving toward systemic applications. Their mRNA platform — naturally transient, non-integrating — addresses the key safety concern of sustained reprogramming factor expression.

The competitive dynamic between Altos, Sinclair's commercial partners, and smaller companies racing toward first human data means the field is moving faster than it would with a single academic lab. That's good for the science; it's also why the marketing noise will intensify well ahead of the clinical evidence.

Timeline: What to Expect and When

The honest summary: the science is real, the timeline is long, and the consumer marketing is significantly ahead of where the evidence is. The most productive posture for 2026 is to follow the published literature, invest in the measurable interventions (NAD+ optimization, senolytics, biomarker tracking, metabolic health), and calibrate expectations to the actual clinical timeline.

Summary: What to Take From This

• Epigenetic reprogramming is the most scientifically grounded anti-aging approach since caloric restriction research — backed by Nobel Prize-winning biology and serious institutional investment.
• Partial reprogramming (OSK factors) has reset biological age markers in multiple mouse tissues, including restoring vision in aged glaucoma models. Human tissue data in vitro is accumulating.
• ER-100 is a protocol-level designation combining OSK reprogramming, NAD+ support, senolytic priming, and epigenetic clock-based tracking. It's being investigated in early human work, not commercially available at therapeutic scale.
• Consumer products claiming "epigenetic reprogramming" are almost universally marketing rebrands of standard supplements with no direct connection to the published research.
• The NAD+ and senolytic components of this science are the most accessible today — with human RCT support and meaningful relevance to the reprogramming biology.
• A clinical reprogramming therapy reaching broad human use is a 2030s story, not a 2026 one. The field is moving fast, but biology has its own timeline.

Frequently Asked Questions

What is epigenetic reprogramming and how is it different from gene editing?

Epigenetic reprogramming changes the pattern of gene expression — which genes are switched on or off — without altering the underlying DNA sequence itself. Gene editing (like CRISPR) changes the DNA code permanently. Reprogramming changes how that code is read, and crucially, those changes may be reversible. In the context of aging, partial reprogramming aims to reset epigenetic "age marks" that accumulate over decades, restoring younger patterns of gene expression without modifying the genome itself.

What is the Sinclair ER-100 protocol and is it available to the public?

ER-100 is a research-stage epigenetic reprogramming protocol associated with the Sinclair lab at Harvard, combining partial reprogramming signals (OSK factors), NAD+ precursors, senolytic priming, and epigenetic clock monitoring. As of 2026, it is not commercially available as a complete therapeutic protocol. Early human safety evaluation is underway for specific components (particularly the optic nerve regeneration application), but systemic human reprogramming at therapeutic scale is several years from broad clinical availability. Consumer products marketed as "ER-100" or "epigenetic reprogramming" are not the same thing as the research protocol.

Has David Sinclair's reprogramming research been independently replicated?

The foundational findings — that partial OSK reprogramming can reset epigenetic age markers in mouse tissue and restore function in aged retinal cells — have been corroborated by independent labs. Altos Labs, Turn Biotechnologies, and groups at the Salk Institute and Stanford have all produced confirming data on partial reprogramming biology. The human translation remains early-stage, but the animal model science is replicated and increasingly consistent.

What are the risks of epigenetic reprogramming?

The primary risk is cancer. Complete cellular reprogramming induces an embryonic-like state that, if sustained, can lead to teratoma formation (benign tumors of mixed cell types) or, in the worst case, malignancy. The partial reprogramming approach addresses this by limiting exposure duration and omitting c-Myc (the most oncogenic of the four Yamanaka factors). To date, tightly controlled brief-exposure protocols in animal models have not shown significant tumorigenic signals, but the long-term safety data window in humans does not yet exist. This is the primary reason systemic human reprogramming remains years away from clinical practice.

How does ER-100 relate to NAD+ supplementation?

NAD+ is a required cofactor for sirtuin proteins, which are central to epigenetic maintenance and DNA repair — the same machinery that partial reprogramming aims to restore. NAD+ precursors (NMN, NR) support the cellular infrastructure that reprogramming depends on. In ER-100-type protocols, NAD+ optimization is part of the foundational stack — not the reprogramming signal itself, but a prerequisite for the cellular environment in which reprogramming is most effective. NAD+ supplementation has human RCT support; the reprogramming components do not yet.

How can I track my biological age to monitor longevity interventions?

Epigenetic clock tests are available from companies including TruMe Health, Elysium Health (Index test), Chronomics, and myDNAge. These use DNA methylation patterns from a blood or saliva sample to estimate biological age using validated algorithms including the Horvath Clock, DunedinPACE, and GrimAge. A baseline measurement followed by retesting after 6–12 months of consistent intervention gives you the signal you need to assess whether your protocol is moving the needle. For the blood work foundation, see: The Blood Work Guide for Longevity.

What longevity interventions have the strongest human evidence right now?

The interventions with the strongest human evidence for longevity biomarker improvement: (1) aerobic exercise and resistance training — the most robustly evidenced longevity intervention, full stop; (2) sleep optimization — consistent 7–9 hour sleep with good architecture; (3) caloric restriction or fasting-mimicking protocols — human trial data from Valter Longo's lab showing epigenetic clock reversal; (4) NAD+ precursor supplementation — multiple RCTs confirming NAD+ elevation with downstream biomarker effects; (5) metformin — observational and early trial data (TAME trial ongoing). See our full breakdown: Metformin & Longevity Research: What the Evidence Shows. For the cognitive protection piece: Wellness Protocols for Dementia Prevention.